Welireg (Belzutifan) for Kidney Cancer: What Patients Should Know

Two Moments in Kidney Cancer Care When Welireg Enters the Conversation

Written By: Nitin Goswami, Senior Medical Content Writer  |  Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)

In kidney cancer, Welireg (belzutifan) usually comes up in one of two situations. In the first, surgery has removed the kidney tumor, the scans look clear, and your oncologist is talking about what could stop the cancer from coming back. In the second, the cancer has already spread, you have been through immunotherapy and a targeted tablet, and you want to know what options are left. Welireg has an approval for each moment — and the two differ in purpose, in evidence, and in what to expect day to day. This guide keeps them apart so you can read the part that matches your situation.

Both uses apply to clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. The approval for use after surgery is the newest — the U.S. FDA granted it on June 12, 2026 — while the approval for advanced disease dates to December 14, 2023.

Welireg for Kidney Cancer at a Glance

Which Situation Sounds Like Yours?

After Kidney Surgery (Adjuvant Use)

• Who: adults with ccRCC at intermediate-high or high risk of recurrence after nephrectomy (kidney removal), or after nephrectomy plus removal of metastatic lesions
• How it's given: Welireg tablets together with pembrolizumab, an immunotherapy given by infusion
• How long: until the cancer returns or side effects become unacceptable, or up to 54 weeks
• The aim: lower the chance of recurrence — there is no visible tumor being treated

When the Cancer Has Spread (Advanced Use)

• Who: adults with advanced ccRCC that has already been treated with a PD-1 or PD-L1 immunotherapy and a VEGF-targeted tablet (a VEGF-TKI)
• How it's given: Welireg on its own, as a once-daily tablet
• How long: until the disease progresses or side effects become unmanageable
• The aim: shrink or hold back tumors that are already there

Welireg is also approved for von Hippel-Lindau (VHL) disease and for pheochromocytoma and paraganglioma — both are covered briefly further down.

Kidney Cancer by the Numbers

Kidney cancer gets far less attention than breast or lung cancer, yet more than 17,000 people are diagnosed with it in India every year. Each figure below names its source and year.

How Many People Are Diagnosed?

• Worldwide (GLOBOCAN 2024, WHO/IARC): 442,570 new cases and 144,871 deaths in a year — 2.1% of all new cancers and 1.5% of all cancer deaths
• India (GLOBOCAN 2024): 17,320 new cases and 6,482 deaths a year, about 47 diagnoses every day. Kidney cancer makes up 1.1% of India's cancers, compared with 3.8% of cancers in the US
• United States (SEER, 2026 estimate, kidney and renal pelvis): 80,450 new cases and 15,160 deaths, with about 688,000 people living with the disease in 2023 and a median age at diagnosis of 65
• Men are affected about twice as often: 24.4 new cases per 100,000 men versus 12.3 per 100,000 women in the US (SEER)
• Clear cell is the main type: it accounts for roughly 75–80% of kidney cancers (JAMA review, 2024)

India's figures are modelled from regional cancer registries rather than counted nationwide, so read them as a reliable order of magnitude, not an exact head-count.

How Far Has It Spread When It Is Found?

• 66% of US cases are found while still confined to the kidney, 17% have reached nearby lymph nodes, and 15% have already spread to distant organs (SEER, 2016–2022)
• Five-year survival (relative survival): about 94% when localized, 78% regional, and 20% once distant — 79% across all stages

(Relative survival compares people with the cancer to the general population. These are averages for large groups, not forecasts for one person.)

Why Recurrence After Surgery Matters

• Surgery is often curative for localized kidney cancer, yet a 2024 review notes that after nephrectomy the risk of recurrence can be as high as 50% for some patients
• Until 2021, there was no adjuvant treatment for kidney cancer backed by strong evidence. Then the KEYNOTE-564 trial showed that pembrolizumab after surgery raised 24-month disease-free survival from 68.1% to 77.3% (New England Journal of Medicine, 2021)
• The newest step is adding Welireg to pembrolizumab — in the LITESPARK-022 trial, 24-month disease-free survival was 80.7% versus 73.7% with pembrolizumab alone (details below)

Those two trials enrolled different patients, so their numbers shouldn't be compared side by side — but together they show how quickly the options after surgery are changing.

Why Clear Cell Kidney Cancer Depends on HIF-2α

Every cell carries an oxygen-sensing system. When oxygen is plentiful, a protein made by the VHL gene helps clear away a family of switches called HIFs (hypoxia-inducible factors). In the majority of clear cell kidney cancers the VHL gene has been inactivated, so the HIF switches pile up and stay "on" — as though the cell were permanently short of oxygen. Of the HIF family, HIF-2α is considered the more cancer-promoting one (Baldewijns et al., 2010).

What Belzutifan Does

Welireg is a first-in-class HIF-2α inhibitor. HIF-2α accumulates in these tumors and switches on genes that drive blood-vessel growth and cell multiplication; belzutifan blocks it, cutting the signal at its source rather than dealing with the consequences.

How That Differs From Your Earlier Treatments

• Immunotherapy (PD-1 or PD-L1 inhibitors, such as pembrolizumab): helps your immune system recognize and attack cancer cells
• VEGF-targeted tablets (VEGF-TKIs): block the receptors that tell tumors to grow new blood vessels
• Belzutifan: blocks HIF-2α, one of the switches that turns those growth signals on in the first place

After Surgery: Welireg Plus Pembrolizumab

Who Counts as Intermediate-High or High Risk?

The LITESPARK-022 trial defined the risk groups from the pathology report of the removed kidney:

• Intermediate-high risk: stage pT2 with grade 4 only, or stage pT3 of any grade with no lymph node involvement and no distant spread
• High risk: stage pT4 of any grade with no nodes or distant spread, or any pT stage of any grade with lymph node involvement and no distant spread
• Metastatic with no evidence of disease (M1 NED): spread that was completely removed surgically along with the kidney tumor

In the trial, 85% of participants were in the intermediate-high group, 6% were high risk, and 9% were M1 NED. Your own category can be read from your pathology report — your oncologist can confirm where you fall.

What the LITESPARK-022 Trial Showed

The trial enrolled 1,841 people after nephrectomy. Everyone received pembrolizumab; half also received Welireg 120 mg daily and half received a placebo tablet, for up to a year (New England Journal of Medicine, 2026).

• Recurrence or death: the Welireg group had a hazard ratio of 0.72 — about a 28% lower risk of recurrence or death than pembrolizumab alone
• 24-month disease-free survival: 80.7% with Welireg plus pembrolizumab versus 73.7% with pembrolizumab plus placebo
• Overall survival: not yet different between the groups. This was an early look with only 29% of the events expected for the final analysis, and 24-month survival was already high in both arms (96.2% versus 95.7%)

The Trade-Off

• Grade 3 or higher side effects occurred in 52.1% of people on Welireg plus pembrolizumab versus 30.2% on pembrolizumab plus placebo
• According to the FDA label, Welireg had to be interrupted in 52% of patients, its dose was reduced in 34%, and 27% stopped it permanently because of side effects
• Serious side effects occurred in 30% of patients, and fatal adverse reactions were reported in 1.1%

Because survival data are still maturing, this is a judgment call: a documented reduction in recurrence risk on one side, more side effects and an unproven survival benefit on the other. That is exactly why the decision has to be individual.

Questions Worth Taking to Your Oncologist

• Which recurrence-risk category does my pathology report place me in?
• Would pembrolizumab alone or pembrolizumab with Welireg make more sense for me?
• How often will my blood counts and oxygen levels be checked?
• What happens if I need a pause or a dose reduction?
• How will we know if the treatment is working, given that there is no tumor to measure?

When the Cancer Has Spread: Welireg on Its Own

The LITESPARK-005 Trial

This trial enrolled 746 people whose clear cell kidney cancer had progressed after PD-1 or PD-L1 immunotherapy and VEGF-targeted therapy. They received either Welireg 120 mg daily or everolimus 10 mg daily, an older targeted tablet, until progression or unacceptable side effects (New England Journal of Medicine, 2024).

• Tumor shrinkage: 21.9% of people on Welireg had a confirmed response versus 3.5% on everolimus. According to the FDA label, 3% of Welireg patients had a complete response
• Durability: among the 82 patients on Welireg who responded, 25 (30%) kept their response for 12 months or longer (FDA label)
• Progression-free survival: the median was 5.6 months in both groups, but at 18 months 24.0% of the Welireg group was alive without progression versus 8.3% on everolimus
• Overall survival: median 21.4 months versus 18.1 months, a difference that did not reach statistical significance
• Tolerability: severe (grade 3 or higher) side effects were similar between the groups (61.8% versus 62.5%), and 5.9% stopped Welireg because of side effects versus 14.7% stopping everolimus

Reading These Numbers Honestly

• About one in five patients had a response — so most people did not have a formal tumor response
• The halfway point for time-to-progression was identical in both groups, which suggests the benefit shows up in a subset of patients, some of whom did well for a long time, rather than across the board
• The survival advantage is not proven. Welireg's approval in this setting rests on tumor response and progression-free survival

Other Approved Uses of Welireg

Von Hippel-Lindau (VHL) Disease

Welireg is approved for adults with VHL disease who need treatment for associated kidney cancer, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors that do not need immediate surgery. Our guide to VHL disease and its treatment explains this use in detail.

Pheochromocytoma and Paraganglioma

• Approved for adults and for children aged 12 and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma
• In a phase 2 trial of 72 people, 26% had a confirmed response, the disease was controlled in 85%, and the median response lasted 20.4 months (New England Journal of Medicine, 2025)
• Children weighing under 40 kg take 80 mg once daily instead of 120 mg

Taking Welireg: Tablets, Timing and Storage

• Dose: 120 mg once daily for adults — the tablets are 40 mg each, so that is three tablets
• Timing: at about the same time every day, with or without food
• Swallow whole: do not chew, crush, or split the tablets
• Supply: the tablets come in bottles of 90, which is a 30-day supply at three tablets a day
• Storage: at room temperature, 20°C to 25°C (68°F to 77°F)

If Something Goes Wrong

• Missed a dose: take it as soon as you remember that same day. If the day has passed, resume normally the next day — never double up
• Vomited after a dose: do not retake it; take the next dose the next day
• Side effects: the dose can be lowered from 120 mg to 80 mg and then to 40 mg. If a further reduction is needed, treatment stops permanently

Safety: What Your Care Team Will Watch

Boxed Warning: Pregnancy and Contraception

Welireg carries the FDA's most serious warning for one reason: exposure during pregnancy can cause harm to an unborn baby. Pregnancy status must be verified before starting.

For Women Who Could Become Pregnant

• Use effective non-hormonal contraception during treatment and for 1 week after the last dose
• Welireg can make some hormonal contraceptives ineffective, so pills, patches, or implants alone are not enough

For Men With Female Partners Who Could Become Pregnant

• Use effective contraception during treatment and for 1 week after the last dose

Anemia

Welireg can cause severe anemia that may need a blood transfusion. Blood counts are checked before starting and periodically throughout treatment.

How Common Is It?

With Pembrolizumab (After Surgery)

Hemoglobin fell in 95% of patients in LITESPARK-022, and 11% had grade 3 or higher anemia. The median time to onset was 42 days.

Welireg Alone (Advanced Cancer)

Hemoglobin fell in 88% of patients in LITESPARK-005, and 29% had grade 3 anemia. The median time to onset was 29 days. Of those who developed anemia, 22% received transfusions only, 20% received erythropoiesis-stimulating agents only, and 12% received both.

What Your Team Does About It

Blood Tests

Expect regular hemoglobin checks. Tell your team promptly if you notice unusual tiredness, dizziness, or pale skin.

Dose Changes

Treatment is paused when hemoglobin drops below a set level, then resumed at the same or a lower dose once it recovers. The threshold depends on why you are taking Welireg:

After Surgery

Withhold Welireg if hemoglobin falls below 9 g/dL or a transfusion is needed, and resume once it is back to 9 g/dL or higher.

All Other Uses

Withhold Welireg if hemoglobin falls below 8 g/dL or a transfusion is needed, and resume once it is back to 8 g/dL or higher.

Hypoxia (Low Blood Oxygen)

• Welireg can cause severe hypoxia that may need supplemental oxygen, a dose change, or hospitalization
• In LITESPARK-005, hypoxia occurred in 15% of patients (10% severe), and 69% of those affected were treated with oxygen. In LITESPARK-022, it occurred in 7% (5% grade 3 or higher)
• Your oxygen saturation is checked before you start and periodically afterward. Report shortness of breath or any breathing difficulty immediately — do not wait for the next appointment

Other Common Side Effects

• With pembrolizumab (after surgery): fatigue (49%, compared with 33% on pembrolizumab alone), diarrhea (23%), dizziness (23%), headache (17%), nausea (16%), and shortness of breath (12%). Liver enzyme increases, lower lymphocyte counts, and higher alkaline phosphatase are also common on blood tests
• Welireg alone (advanced cancer): low hemoglobin, fatigue, musculoskeletal pain, and raised creatinine, along with changes in lymphocytes, sodium, potassium, and liver enzymes on blood tests

Medicines That Interact

• Drugs that inhibit UGT2B17 or CYP2C19 can raise belzutifan levels and increase the risk of anemia and hypoxia — your dose may need to be lowered
• Welireg can weaken medicines that are sensitive CYP3A4 substrates, so these are best avoided alongside it
• Tell your oncologist about every medicine you take, including hormonal contraceptives and over-the-counter products

Getting Welireg in India

As of currently available public information, Welireg is not commercially marketed in India. It is a prescription-only medicine, but it can still be imported legally for an individual patient through a Named Patient Program — a regulated route for medicines not yet registered in the country. In practice, you will need:

• A valid prescription from a qualified medical oncologist, who must also start and supervise treatment
• Diagnostic reports, including your histopathology and details of previous treatments
• A Government of India ID proof for the patient, since the medicine is imported in the patient's own name

The Welireg product page explains the process step by step, and our oncology access program covers other targeted cancer medicines that follow the same pathway.

Not Sure Which Situation Fits Yours?

Whether Welireg is an option depends on details that only your reports can answer — whether your kidney cancer is clear cell, what your pathology says about recurrence risk, and which treatments you have already had. Send our team those reports and we will explain what the access process would involve, with no cost and no obligation. Get in touch here.

Quick-Reference Summary

• Welireg (belzutifan) is a once-daily HIF-2α inhibitor tablet approved for two kidney cancer situations: after surgery in combination with pembrolizumab (June 2026), and alone for advanced disease after immunotherapy and a VEGF-TKI (December 2023).
• More than 17,000 people are diagnosed with kidney cancer in India each year, and about 80% of kidney cancers are clear cell (GLOBOCAN 2024; JAMA 2024).
• After surgery, adding Welireg to pembrolizumab lowered the risk of recurrence or death by about 28%, at the cost of more side effects; survival data are still maturing.
• In advanced disease, about 22% of patients had a tumor response versus 3.5% on everolimus, and some responses lasted a year or longer.
• Anemia and low oxygen levels are the two main monitored risks, and pregnancy must be avoided — non-hormonal contraception is required during treatment and for a week afterward.
• Welireg is not commercially marketed in India but can be imported legally through a Named Patient Program with an oncologist's prescription.

Frequently Asked Questions

Is Welireg a chemotherapy drug?

No. Chemotherapy attacks fast-dividing cells throughout the body, while Welireg is a targeted tablet that blocks one specific protein, HIF-2α. After surgery it is paired with pembrolizumab, which is an immunotherapy — also not chemotherapy.

Does Welireg work for kidney cancers that aren't the clear cell type?

The kidney cancer approvals are written for renal cell carcinoma with a clear cell component. Your pathology report states your tumor type, and your oncologist can tell you whether Welireg applies — for other types it is not an approved option.

Can Welireg cure kidney cancer?

No trial describes it as a cure. After surgery, it lowered the risk of recurrence when added to pembrolizumab. In advanced cancer, about one in five patients had a response, complete responses were uncommon (3%), and some responses lasted a year or longer.

I'm receiving pembrolizumab alone after surgery. Can Welireg be added?

The approved adjuvant use is in combination with pembrolizumab, and in the trial participants were randomized to pembrolizumab with either Welireg or a placebo. Whether adding it now suits you — including timing and how you have tolerated pembrolizumab so far — is a decision for your oncologist.

Why are blood tests and oxygen checks part of the treatment?

Because anemia and low blood oxygen are the two most important risks. Hemoglobin fell in 88–95% of trial patients, and hypoxia occurred in up to 15%. Regular checks let your team pause or lower the dose before either becomes serious.

Can I keep using my hormonal birth control?

Not on its own. Welireg can make some hormonal contraceptives ineffective, so effective non-hormonal contraception is needed during treatment and for 1 week after the last dose. Do not change your contraception without discussing it with your doctor.

How do I get Welireg in India?

It is not commercially marketed in India, but it can be imported in the patient's own name through a regulated Named Patient Program with a prescription from a medical oncologist, your diagnostic reports, and a Government of India ID proof.

How can I be sure the Welireg I receive is genuine?

Ask where it comes from. A bottle bought from an unregulated online seller can look identical to the real thing while holding an incorrect dose, expired tablets, or medicine that was stored badly — and you cannot tell by looking. Welireg is a prescription-only cancer medicine, and through Named Patient Program it is supplied only against a valid oncologist's prescription, sourced from the manufacturer's authorized network, and documented with batch traceability, so the bottle that reaches you can be traced back to its source.

References

1. U.S. Food and Drug Administration. FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma, June 12, 2026.
2. U.S. Food and Drug Administration. FDA Approves Belzutifan for Advanced Renal Cell Carcinoma, December 14, 2023.
3. DailyMed (National Library of Medicine). WELIREG (belzutifan) Prescribing Information.
4. Choueiri TK, et al. Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma (LITESPARK-022), New England Journal of Medicine 2026;395.
5. Choueiri TK, et al. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma (LITESPARK-005), New England Journal of Medicine 2024;391.
6. Jimenez C, et al. Belzutifan for Advanced Pheochromocytoma or Paraganglioma (LITESPARK-015), New England Journal of Medicine 2025;393.
7. Choueiri TK, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma (KEYNOTE-564), New England Journal of Medicine 2021;385.
8. Baldewijns MM, et al. VHL and HIF Signalling in Renal Cell Carcinogenesis, Journal of Pathology 2010;221.
9. Rose TL, et al. Renal Cell Carcinoma: A Review, JAMA 2024;332.
10. Bueno AN, et al. Adjuvant Therapy in Renal Cell Carcinoma (RCC): Progress, at Last, Translational Cancer Research 2024;13.
11. National Cancer Institute SEER Program. Cancer Stat Facts: Kidney and Renal Pelvis Cancer.
12. International Agency for Research on Cancer (WHO). GLOBOCAN 2024: World Fact Sheet.
13. International Agency for Research on Cancer (WHO). GLOBOCAN 2024: India Fact Sheet.